Pan Hung-Wei, Ou Yueh-Hsing, Peng Shian-Yang, Liu Shu-Hsian, Lai Po-Lin, Lee Po-Hwaung, Sheu Jin-Chuan, Chen Chi-Ling, Hsu Hey-Chi
Graduate Institute of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan.
Cancer. 2003 Jul 1;98(1):119-27. doi: 10.1002/cncr.11487.
Intrahepatic metastasis via portal vein spread is an important feature and a crucial unfavorable prognostic factor of hepatocellular carcinoma (HCC). To identify the molecular factors for tumor progression, the authors used differential display (DD) to analyze aberrant gene expression in HCC. The goal of the current study was to elucidate the clinicopathologic and prognostic significance of osteopontin (OPN) in HCC progression.
OPN mRNA levels, which were increased preferentially in HCC in a DD assay and verified with Northern blotting, were measured in 240 surgically removed, unifocal, primary HCCs using the reverse transcription-polymerase chain reaction at the exponential phase. OPN mRNA expression was correlated with clinicopathologic features, particularly portal vein invasion, early tumor recurrence, and prognosis.
Osteopontin mRNA was overexpressed in 133 tumors (55%). The OPN overexpression was associated closely with alpha-fetoprotein elevation (P = 0.001), p53 mutation (P = 0.021), larger tumors (P = 0.002), high-grade HCC (P < 0.001), late-stage HCC (P < 0.001), early tumor recurrence and/or metastasis (P = 0.003), and a lower 10-year survival rate (P = 0.00013). Multivariate analysis revealed that tumor stage and early tumor recurrence were crucial prognostic factors. In early-stage HCC, which has no vascular invasion and a lower early tumor recurrence than late-stage HCC, OPN mRNA overexpression predicted a higher early recurrence rate (P = 0.003).
OPN mRNA overexpression was correlated closely with high-grade, late-stage, and early tumor recurrence, which lead to poorer prognosis. Osteopontin overexpression might serve as an unfavorable prognostic factor and a useful marker for predicting early recurrence in early-stage HCC.
经门静脉播散的肝内转移是肝细胞癌(HCC)的一个重要特征及关键的不良预后因素。为了确定肿瘤进展的分子因素,作者采用差异显示(DD)技术分析HCC中异常的基因表达。本研究的目的是阐明骨桥蛋白(OPN)在HCC进展中的临床病理及预后意义。
在240例手术切除的单灶性原发性HCC中,于指数期采用逆转录-聚合酶链反应检测OPN mRNA水平,该水平在DD分析中优先在HCC中升高并经Northern印迹法验证。OPN mRNA表达与临床病理特征相关,尤其是门静脉侵犯、早期肿瘤复发及预后。
133例肿瘤(55%)中骨桥蛋白mRNA过度表达。OPN过度表达与甲胎蛋白升高(P = 0.001)、p53突变(P = 0.021)、肿瘤较大(P = 0.002)、高级别HCC(P < 0.001)、晚期HCC(P < 0.001)、早期肿瘤复发和/或转移(P = 0.003)以及较低的10年生存率(P = .00013)密切相关。多因素分析显示肿瘤分期和早期肿瘤复发是关键的预后因素。在无血管侵犯且早期肿瘤复发低于晚期HCC的早期HCC中,OPN mRNA过度表达预示着较高的早期复发率(P = 0.003)。
OPN mRNA过度表达与高级别、晚期及早期肿瘤复发密切相关,导致预后较差。骨桥蛋白过度表达可能是一个不良预后因素及预测早期HCC早期复发的有用标志物。